Recurrence of benign meningiomas: Predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression

British Journal of Neurosurgery

Volumn 25, Issue 6, 2011, Pages 707-713

  Abdelzaher, Eman ^a   El Gendi, Saba Mohamed ^a   Yehya, Ahmed ^a   Gowil, Ahmed Gaber ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Benign meningioma; biological markers; immunohistochemistry; recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BONE; BRAIN MENINGIOMA; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENINGIOMA; MORPHOMETRICS; PATHOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SOFT TISSUE; TUMOR RECURRENCE;

ADULT; AGED; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82355161661     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2010.522743     Document Type: Article

References (29)

1. Monz D, Munnia A, Comtesse N, et al. Novel Tankyrase-related Gene Detected with Meningioma-specific Sera. Clin Cancer Res 2001;7:113-19. (Pubitemid 32110213)
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of tumors of the central nervous system. 4th edition. Lyon: IARC Press, 2007.
3. Kolles H, Niedermayer I, Schmitt CH, et al. Triple approach for diagnosis and grading of meningiomas: histology, morpho-metry of Ki-67/Feulgen stainings and cytogenetics. Acta Neurochir 1995;137:174-81. (Pubitemid 26002584)
4. Mirimanoff RO, Dosoretz DE, Linggood RM, et al. Menin-gioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985;62:18-24. (Pubitemid 15199399)
5. Korshunov AG, Shishkina LV, Golanov AV. Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value. Arkh Patol 2002;64(1):29-33.
6. Takei H, Buckleair LW, Powell SZ. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas. Neuropathology 2008;28:62-8.
7. Konstantinidou AE, Korkolopoulou P, Mahera H, et al. Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 2003;43:280-90. (Pubitemid 37115062)
8. Karamitopoulou E, Perentes E, Tolnay M, Probst A. prognostic significance of MIB-I, p53, and bcl-2 immunor-eactivity in meningiomas. Hum Pathol 1998;29:140-5. (Pubitemid 28099509)
9. Matsuno A, Fujimaki T, Saaki T, et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 1996;91: 504-10. (Pubitemid 26133662)
10. Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol 1998;29:1420-7. (Pubitemid 28563974)
11. Amatya VJ, Takeshima Y, Sugiyama K, et al. Immunohisto-chemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 2001;32(9):970-5. (Pubitemid 32911320)
12. Wahab M, Al-Azzawi F. Meningioma and hormonal influences. Climacteric 2003;6(4):285-92. (Pubitemid 38112898)
13. Benzel EC, Gelder FB. Correlation between sex hormone binding and peritumoral edema in intracranial meningiomas. Neurosurgery 1988;23(2):169-74.
14. Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 2006;105(2):163-73.
15. Blankenstein MA, Koehorst SG, van der Kallen CJ, et al. Oestrogen receptor independent expression of progestin receptors in human meningioma-a review. J Steroid Biochem Mol Biol 1995;53:361-5.
16. Konstantinidou A, Korkolopoulou P, Patsouris E, et al. Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas. J Neurooncol 2001;55:1-9. (Pubitemid 34023620)
17. Verheijen FM, Donker GH, SalesViera C, et al. Progesterone receptor, bcl-2 and Bax expression in meningiomas. J Neurooncol 2002;56: 35-41. (Pubitemid 34256616)
18. Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH. Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 2000;65(10-11):795-800.
19. Miyagami M, Kanou T, Nakamura S. P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas. No To Shinkei 1996;48(8):719-25. (Pubitemid 26281641)
20. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol Res Pract 2000;196(7):483-8. (Pubitemid 30459148)
21. Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 2006;37:415-21.
22. Maiuri F, De Caro Mdel B, Esposito F, et al. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 2007;82(1): 63-8.
23. Kim YJ, Ketter R, Henn W, Zang KD, Steudel WI, Feiden W. Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch 2006;449(5):529-38. (Pubitemid 44722321)
24. Salmon I, Kiss R, Levivier M, et al. Characterization of nuclear DNA content, proliferation index, and nuclear size in a series of 181 meningiomas, including benign primary, recurrent, and malignant tumors. Am J Surg Pathol 1993;17:239-47. (Pubitemid 23085918)
25. Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. Surg Neurol 1986;26(5):461-9. (Pubitemid 16006137)
26. Schiffer D, Ghimenti C, Fiano V. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J Neurooncol 2005;73(2): 125-30. (Pubitemid 40974032)
27. Terzi A, Saglam EA, Barak A, Soylemezoglu F. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract 2008;204(5):305-14.
28. Hakin-Smith V, Battersby RD, Maltby EL, Timperley WR, Royds JA. Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence. Neuropathol Appl Neurobiol 2001;27(1):40-9. (Pubitemid 32291187)
29. Kamei Y, Watanabe M, Nakayama T, Kanamaru K, Waga S, Shiraishi T. Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas. J Neurooncol 2000;46(3): 205-13. (Pubitemid 30410150)